The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Condition:   HIV Infections Interventions:   Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets;   Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   International Maternal Pediatric Adolescent AIDS Clinical Trials Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Mental Health (NIMH);   ViiV Hea lthcare Ltd. Not yet recruiting (Source: ClinicalTrials.gov)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2C22TL0